Knocking down ZNF423 or CALML3 altered the breast cancer cell response to several drugs including 4-OH-TAM, raloxifene, olaparib (PARP inhibitor) and cisplatin (platinum). This evidence concerns the gene ZNF423 and breast carcinoma.